Previous 10 | Next 10 |
Worldwide Ocaliva ® net sales of $83.3 million and $312.7 million for the fourth quarter and full year 2020, representing 18% and 25% growth over the prior year Intercept provides initial 2021 Worldwide Ocaliva Net Sales Guidance of $325 million to $355 millio...
Intercept Pharma (NASDAQ:ICPT) is scheduled to announce Q4 earnings results on Thursday, February 25th, before market open.The consensus EPS Estimate is -$1.59 (+46.8% Y/Y) and the consensus Revenue Estimate is $84.89M (+18.7% Y/Y).Net Ocaliva sales estimate $84.2M.Over the last 2 years, ICPT...
H.C. Wainwright analyst Ed Arce has downgraded shares of Intercept Pharmaceuticals (ICPT) from neutral to sell.He also cut his price target to $25 from $46.Arce writes that yesterday's announcement in an SEC Form 8-K that Chief Medical Officer Jason Campagna will resign effective March 5 does...
NEW YORK, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced the appointment of Dagmar Rosa-Bjorkes...
Intercept Pharmaceuticals (ICPT) appointed Linda Richardson as Chief Commercial Officer responsible for overseeing Ocaliva franchise in the U.S. and International regions, as well as commercial strategy and execution for future indications and product opportuniti...
Lisa DeFrancesco, Senior Vice President, Corporate Affairs & Investor Relations, will join Intercept’s Executive Leadership Team NEW YORK, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the develop...
DUBLIN, Ireland, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in adults with narcolepsy, to...
NEW YORK, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its fourth quarter and full year 2020 fi...
Intercept Pharmaceuticals (ICPT) rejects reports that the FDA has reached a conclusion on the status of a newly identified safety signal (“NISS”) for Ocaliva® (obeticholic acid). The stock is now trading ~9.8% higher, after a rise of as much as ~11.8% in morning h...
NEW YORK, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that an analyst note commenting on the...
News, Short Squeeze, Breakout and More Instantly...
Intercept Pharmaceuticals Inc. Company Name:
ICPT Stock Symbol:
NASDAQ Market:
Intercept Pharmaceuticals Inc. Website:
MORRISTOWN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced five abs...
sNDA intended to satisfy post-marketing requirements to confirm a clinical benefit in patients with PBC Precedent-setting submission includes data from post-marketing studies COBALT and Study 401 as well as real-world evidence from a claims database and patient registries FDA has assign...
Data from two Phase 2 studies in PBC show combination of OCA + bezafibrate achieved biochemical remission (normalization of ALP, total bilirubin, GGT, ALT and AST) in 40-44% of patients in the first 12 weeks OCA 5 or 5-10 mg + bezafibrate 400 mg cohorts in both studies showed a >60% ...